Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 16 · below the Ichimoku cloud · RSI 40 · MACD above its signal
None of the 29 investors followed here reported a position in BCAB in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BCAB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -52.6 | -8.2 | -34.8 | -47.7 | -6.7 | 5.3 | -20.5 | -48.6 | -23.1 | 0.0 | −95.4% | ||
| 2025 | -20.5 | -30.6 | 6.4 | 40.1 | -15.8 | -3.2 | -9.3 | 27.0 | 50.9 | 1.6 | 29.3 | -37.2 | −3.9% |
| 2024 | -22.2 | 41.0 | 27.4 | -34.4 | -33.0 | -9.3 | 32.1 | -2.2 | -0.6 | 9.1 | -12.5 | -64.8 | −76.0% |
| 2023 | -54.1 | -21.4 | -10.1 | 25.7 | -6.5 | -4.8 | -0.3 | -16.1 | -32.3 | -13.5 | 20.4 | 39.0 | −70.2% |
| 2022 | -51.3 | -32.2 | -22.8 | -30.4 | -30.7 | 18.3 | 19.3 | 156.2 | -11.6 | -10.5 | 59.8 | -25.1 | −58.0% |
| 2021 | 29.3 | 20.8 | -4.3 | -2.5 | -13.2 | -1.6 | -3.3 | 0.2 | -28.4 | -0.7 | -13.6 | -22.3 | −42.3% |
| 2020 | — |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 10, 2026 | Short Jay MChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 430K | — |
| Mar 9, 2026 | Vasquez Christian JChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 240K | — |
| Mar 9, 2026 | Sievers Eric LOfficer | Stock Award(Grant) at price 0.00 per share. | 240K | — |
| Jun 17, 2025 | Steinman LawrenceDirector | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Jun 17, 2025 | Moran SusanDirector | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Jun 17, 2025 | Gray Mary AnnDirector | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Jun 17, 2025 | Mcbrinn SylviaDirector | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Jun 17, 2025 | Smith Scott AndrewDirector | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Jun 17, 2025 | Williams EddieDirector | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Mar 11, 2025 | Short Jay MChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 431K | — |
| Mar 10, 2025 | Waldron Richard AChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Mar 10, 2025 | Vasquez Christian JOfficer | Stock Award(Grant) at price 0.00 per share. | 85K | — |
| Mar 10, 2025 | Sievers Eric LOfficer | Stock Award(Grant) at price 0.00 per share. | 175K | — |
No analyst coverage for this instrument.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
No recent headlines.